(JAZZ) Jazz Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 11.638m USD | Total Return: 74.8% in 12m

Sleep Disorders, Seizures, Cancer Treatments
Total Rating 55
Safety 73
Buy Signal 0.54
Biotechnology +3.6
Pharmaceuticals +2.0
Market Cap: 11,638m
Avg Trading Vol: 149M USD
ATR: 2.77%
Peers RS (IBD): 68.5
Risk 5d forecast
Volatility31.0%
Rel. Tail Risk-8.48%
Reward TTM
Sharpe Ratio1.05
Alpha39.91
Character TTM
Beta0.386
Beta Downside-0.003
Drawdowns 3y
Max DD33.56%
CAGR/Max DD0.25
EPS (Earnings per Share) EPS (Earnings per Share) of JAZZ over the last years for every Quarter: "2021-03": 3.92, "2021-06": 3.9, "2021-09": 4.2, "2021-12": 4.21, "2022-03": 3.73, "2022-06": 4.3, "2022-09": 5.17, "2022-12": -0.07, "2023-03": 3.95, "2023-06": 4.51, "2023-09": 4.84, "2023-12": 5.02, "2024-03": 2.68, "2024-06": 5.3, "2024-09": 6.61, "2024-12": 6.6, "2025-03": -1.52, "2025-06": -8.25, "2025-09": 8.13, "2025-12": 6.64,
EPS CAGR: 16.62%
EPS Trend: -20.0%
Last SUE: 0.05
Qual. Beats: 0
Revenue Revenue of JAZZ over the last years for every Quarter: 2021-03: 607.581, 2021-06: 751.811, 2021-09: 838.115, 2021-12: 896.731, 2022-03: 813.721, 2022-06: 932.878, 2022-09: 940.652, 2022-12: 972.123, 2023-03: 892.812, 2023-06: 957.317, 2023-09: 972.14, 2023-12: 1011.935, 2024-03: 901.983, 2024-06: 1023.825, 2024-09: 1054.969, 2024-12: 1088.173, 2025-03: 897.841, 2025-06: 1045.712, 2025-09: 1126.107, 2025-12: 1197.926,
Rev. CAGR: 10.86%
Rev. Trend: 75.3%
Last SUE: 0.80
Qual. Beats: 0
Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: JAZZ Jazz Pharmaceuticals

Jazz Pharmaceuticals plc develops and sells pharmaceutical products across various international markets. The companys portfolio includes treatments for rare diseases and oncology. This business model is common in the pharmaceutical sector, which often focuses on specialized, high-need areas.

Key products address conditions like narcolepsy, epilepsy, and acute lymphoblastic leukemia. Jazz also maintains a pipeline of drugs in various clinical trial phases, from Phase 1 to Phase 3, targeting conditions such as HER2-positive cancers and diffuse glioma. Pharmaceutical companies frequently engage in licensing and collaboration agreements to expand their research and development capabilities.

Further research on ValueRay can provide deeper insights into specific product performance and market dynamics.

Headlines to Watch Out For
  • Xywav sales growth drives revenue expansion
  • Epidiolex sales contribute significantly to net income
  • Rylaze demand impacts oncology segment performance
  • Pipeline development costs influence profitability
  • Regulatory approvals for new drugs unlock market access
Piotroski VR‑10 (Strict) 4.0
Net Income: -356.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.60 > 1.0
NWC/Revenue: 45.07% < 20% (prev 88.24%; Δ -43.17% < -1%)
CFO/TA 0.12 > 3% & CFO 1.36b > Net Income -356.1m
Net Debt (4.02b) to EBITDA (139.1m): 28.88 < 3
Current Ratio: 1.86 > 1.5 & < 3
Outstanding Shares: last quarter (61.0m) vs 12m ago -0.84% < -2%
Gross Margin: 88.21% > 18% (prev 0.89%; Δ 8.73k% > 0.5%)
Asset Turnover: 36.06% > 50% (prev 33.87%; Δ 2.18% > 0%)
Interest Coverage Ratio: -2.07 > 6 (EBITDA TTM 139.1m / Interest Expense TTM 195.1m)
Altman Z'' 1.05
A: 0.16 (Total Current Assets 4.17b - Total Current Liabilities 2.24b) / Total Assets 11.66b
B: 0.06 (Retained Earnings 646.2m / Total Assets 11.66b)
C: -0.03 (EBIT TTM -402.9m / Avg Total Assets 11.84b)
D: 0.01 (Book Value of Equity 77.6m / Total Liabilities 7.34b)
Altman-Z'' Score: 1.05 = BB
Beneish M -3.02
DSRI: 1.11 (Receivables 830.7m/716.8m, Revenue 4.27b/4.07b)
GMI: 1.01 (GM 88.21% / 89.05%)
AQI: 1.04 (AQ_t 0.62 / AQ_t-1 0.60)
SGI: 1.05 (Revenue 4.27b / 4.07b)
TATA: -0.15 (NI -356.1m - CFO 1.36b) / TA 11.66b)
Beneish M-Score: -3.02 (Cap -4..+1) = AA
What is the price of JAZZ shares? As of April 06, 2026, the stock is trading at USD 186.95 with a total of 695,900 shares traded.
Over the past week, the price has changed by +2.07%, over one month by +1.81%, over three months by +7.20% and over the past year by +74.83%.
Is JAZZ a buy, sell or hold? Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.
  • StrongBuy: 10
  • Buy: 6
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the JAZZ price?
Wallstreet Target Price 223.5 19.6%
Analysts Target Price 223.5 19.6%
JAZZ Fundamental Data Overview as of 02 April 2026
P/E Forward = 6.8966
P/S = 2.7271
P/B = 2.2456
P/EG = 6.0482
Revenue TTM = 4.27b USD
EBIT TTM = -402.9m USD
EBITDA TTM = 139.1m USD
Long Term Debt = 4.33b USD (from longTermDebt, last quarter)
Short Term Debt = 1.03b USD (from shortTermDebt, last quarter)
Debt = 5.41b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.02b USD (from netDebt column, last quarter)
Enterprise Value = 14.61b USD (11.64b + Debt 5.41b - CCE 2.44b)
Interest Coverage Ratio = -2.07 (Ebit TTM -402.9m / Interest Expense TTM 195.1m)
EV/FCF = 11.70x (Enterprise Value 14.61b / FCF TTM 1.25b)
FCF Yield = 8.55% (FCF TTM 1.25b / Enterprise Value 14.61b)
FCF Margin = 29.24% (FCF TTM 1.25b / Revenue TTM 4.27b)
Net Margin = -8.35% (Net Income TTM -356.1m / Revenue TTM 4.27b)
Gross Margin = 88.21% ((Revenue TTM 4.27b - Cost of Revenue TTM 503.3m) / Revenue TTM)
Gross Margin QoQ = none% (prev 77.11%)
Tobins Q-Ratio = 1.25 (Enterprise Value 14.61b / Total Assets 11.66b)
Interest Expense / Debt = 0.84% (Interest Expense 45.4m / Debt 5.41b)
Taxrate = 2.34% (4.88m / 208.3m)
NOPAT = -393.5m (EBIT -402.9m * (1 - 2.34%)) [loss with tax shield]
Current Ratio = 1.86 (Total Current Assets 4.17b / Total Current Liabilities 2.24b)
Debt / Equity = 1.25 (Debt 5.41b / totalStockholderEquity, last quarter 4.32b)
Debt / EBITDA = 28.88 (Net Debt 4.02b / EBITDA 139.1m)
Debt / FCF = 3.22 (Net Debt 4.02b / FCF TTM 1.25b)
Total Stockholder Equity = 4.04b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.01% (Net Income -356.1m / Total Assets 11.66b)
RoE = -8.82% (Net Income TTM -356.1m / Total Stockholder Equity 4.04b)
RoCE = -4.81% (EBIT -402.9m / Capital Employed (Equity 4.04b + L.T.Debt 4.33b))
 RoIC = -4.18% (negative operating profit) (NOPAT -393.5m / Invested Capital 9.40b)
 WACC = 5.27% (E(11.64b)/V(17.05b) * Re(7.34%) + D(5.41b)/V(17.05b) * Rd(0.84%) * (1-Tc(0.02)))
Discount Rate = 7.34% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -6.44%
[DCF] Terminal Value 88.07% ; FCFF base≈1.29b ; Y1≈1.53b ; Y5≈2.38b
[DCF] Fair Price = 1.06k (EV 69.31b - Net Debt 4.02b = Equity 65.29b / Shares 61.6m; r=6.0% [WACC]; 5y FCF grow 19.69% → 3.0% )
EPS Correlation: -19.97 | EPS CAGR: 16.62% | SUE: 0.05 | # QB: 0
Revenue Correlation: 75.34 | Revenue CAGR: 10.86% | SUE: 0.80 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.95 | Chg7d=+0.046 | Chg30d=+0.516 | Revisions Net=+2 | Analysts=15
EPS current Year (2026-12-31): EPS=23.93 | Chg7d=+0.107 | Chg30d=+2.816 | Revisions Net=+13 | Growth EPS=+185.6% | Growth Revenue=+4.1%
EPS next Year (2027-12-31): EPS=24.95 | Chg7d=-0.003 | Chg30d=+0.352 | Revisions Net=-1 | Growth EPS=+4.2% | Growth Revenue=+7.8%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle